FCRL1
FCRL1 (Fc receptor like 1, also known as FCRH1, IRTA5, IFGP1 and CD307a) is a type I transmembrane surface glycoprotein preferentially expressed by B-cells. It regulates B-cell receptor-mediated signalling responses. Browse Assay Genie's current range of FCRL1 research reagents below, or read on for the biology behind the target.
FCRL1 is a type I transmembrane surface glycoprotein preferentially expressed by B-cells, where it regulates signalling responses downstream of the B-cell receptor (BCR). It recruits ABL1 as an intracellular effector molecule to enhance B-cell activation. It also has a negative role, suppressing ERK activation under both homeostatic and BCR-stimulated conditions in a GRB2-dependent manner. This dual activity makes the FCRL1 protein a useful subject for studies of how B-cell signalling is tuned.
The FCRL1 gene encodes a member of the immunoglobulin receptor superfamily and is one of several Fc receptor-like glycoproteins clustered on the long arm of chromosome 1. The encoded protein contains three extracellular C2-like immunoglobulin domains, a transmembrane domain and a cytoplasmic domain with two immunoreceptor tyrosine-based activation motifs. Alternative splicing results in multiple transcript variants. The protein is localised to the cell membrane, and a mouse ortholog, Fcrl1, is recorded.
HGNC classifies FCRL1 within the CD molecules, immunoglobulin-like domain-containing proteins and Fc receptors gene groups. It has been known as Fc receptor-like 1, FCRH1, IRTA5, IFGP1 and CD307a. NCBI Gene notes that the protein may play a role in the regulation of cancer cell growth, although this is described as a possibility rather than an established function.
FCRL1 regulates BCR-mediated signalling responses and recruits ABL1 to enhance B-cell activation, making it relevant to studies of receptor-proximal signalling.
FCRL1 suppresses ERK activation in a GRB2-dependent manner under homeostatic and BCR-stimulated conditions, offering a route into negative regulation of B-cell signalling.
As one of several Fc receptor-like glycoproteins clustered on chromosome 1, FCRL1 is studied alongside related immunoglobulin superfamily receptors.
NCBI Gene reports that FCRL1 may play a role in the regulation of cancer cell growth, prompting investigation in tumour biology.
FCRL1 is a B-cell surface glycoprotein that regulates BCR-mediated signalling. It recruits ABL1 as an intracellular effector to enhance B-cell activation, and it also suppresses ERK activation in a GRB2-dependent manner under homeostatic and BCR-stimulated conditions.
FCRL1 is also called Fc receptor-like protein 1, FCRH1, IRTA5, IFGP1 and CD307a. Its previous HGNC name was Fc receptor-like 1. NCBI Gene notes that alternative splicing produces multiple transcript variants, so literature may describe more than one form.
A mouse ortholog, Fcrl1, is recorded; check the datasheet of any product for its validated reactivity. NCBI Gene states that FCRL1 may play a role in the regulation of cancer cell growth, but no further disease link is given in the source data.
Other Fc receptor-like proteins from the same chromosome 1 cluster, with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q96LA6; product specifications from Assay Genie datasheets.